林业发展局批准Journavx,这是Vertex制药公司新的止痛药,旨在降低阿片类药物的风险。 FDA approves Journavx, a new painkiller by Vertex Pharmaceuticals, aimed at reducing opioid risks.

林业发展局批准了Vertex制药公司的新止痛药Journavx,旨在降低与类阿片有关的吸毒成瘾和吸毒过量的风险。 The FDA has approved Vertex Pharmaceuticals' new painkiller, Journavx, designed to reduce risks of addiction and overdose linked with opioids. 作为20多年来第一次新的疼痛治疗, Journavx在到达大脑前堵住疼痛信号, 与类阿片不同。 As the first new pain treatment in over 20 years, Journavx blocks pain signals before they reach the brain, unlike opioids. 它为短期疼痛提供了缓解,但并未超过类阿片-丙氨基苯混合物的效绩。 It offers relief for short-term pain but has not outperformed opioid-acetaminophen combinations. 常见副作用包括恶心、便秘、痒痒、皮疹和头痛等。 Common side effects include nausea, constipation, itching, rash, and headache. 尽管成效不大,但它是类阿片和场外镇痛缓解剂的一种有希望的替代物。 Despite modest effectiveness, it represents a promising alternative to opioids and over-the-counter pain relievers.